menu
    • menu
    [{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series B Financing","leadProduct":"ARM210","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"ARMGO Pharma \/ Forbion","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Pharma \/ Forbion"},{"orgOrder":0,"company":"ARMGO Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ARM210","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"ARMGO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ARMGO Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ARMGO Pharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for ARM210

    Menu

    ARM210

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ARMGO Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            ARMGO Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARM210

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorph...

                            Details : ARM210 (also known as S48168), for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). By binding and stabilizing the leaky channel, it can restore normal function, as demonstrated in animal models and in high resolution struct...

                            Product Name : ARM210

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 19, 2023

                            Lead Product(s) : ARM210

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ARMGO Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            ARMGO Pharma

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ARM210

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Forbion

                            Deal Size : $35.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            ARMGO Pharma Raises $35 Million to Progress Clinical Studies of Lead Molecule ARM210 in Cardiac and Skeletal M...

                            Details : Proceeds will fund further clinical development of its lead asset, ARM210, for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) as well as other cardiac and skeletal muscle indications.

                            Product Name : S48168

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 20, 2021

                            Lead Product(s) : ARM210

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Forbion

                            Deal Size : $35.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth